Drug Profile
Research programme: antibody therapeutics - Adimab/Surface Oncology
Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Adimab
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 08 Sep 2023 Surface Oncology has been acquired by Coherus BioSciences
- 28 Mar 2019 No recent reports of development identified for research development in Unspecified in USA
- 07 Mar 2019 Surface Oncology entered into an amended and restated development and option agreement, which amended and restated the development and option agreement with Adimab dated July 2014, for the discovery and optimization of proprietary antibodies as potential therapeutic products